Elizabeth Cairns
Senior Writer
Latest From Elizabeth Cairns
What's Next For Phase II ADCs
BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.
Big Pharma Leads Development Of Novel Antibody-Drug Conjugates
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.
Merck KGaA Suffers Another Late-Stage Loss
After the Phase III failure of xevinapant, the German group will need to cut deals and do better in a rare cancer if it is to turn its fortunes around.
ADA: Zepbound Could Take Sleep Apnea Patients Off CPAP
Lilly’s incretin looks set to add obstructive sleep apnea to its label – an indication in which Novo Nordisk has so far shown no interest.
Truqap Proves False For AstraZeneca
The company’s attempt to move the ALT inhibitor into first-line triple-negative breast cancer proves a dud with the failure of the CAPItello-290 Phase III trial.
Cagrisema Leads The Charge For 2025
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.